ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Artificial Internalizing Receptors for Targeted Degradation of Extracellular Proteins.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial Internalizing Receptors for Targeted Degradation of Extracellular Proteins.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Artificial internalizing receptors are developed, and it is demonstrated that these small organic molecules are powerful agents for capturing and removing the cognate protein of interest from the extracellular space. Toward the overall goal, a range of candidate receptor molecules is synthesized, and the leads are selected based on the highest efficacy of protein capture and internalization by the receptor-engineered cells. Receptor performance is validated in model T lymphoblasts, donor-derived peripheral blood mononuclear cells, and hepatocytes. The capture and depletion are achieved over successive additions of the extracellular target protein. In contrast to pan-IgG degraders, artificial receptors depleted the one, cognate immunoglobulin, leaving the pool of non-cognate proteins un-altered. In an in vitro model system, mimicking hepatic removal of the target protein, receptor-engineered scavenger hepatocytes captured the protein of interest and prevented its association with the cognate receptor on the responder lymphoblasts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.